血圧異常治療薬の世界市場:開発パイプラインレビュー2018

GBI Researchが発行した調査報告書(DATA809020)
◆英語タイトル:Blood Pressure Disorders Drug Development Pipeline Review, 2018
◆商品コード:DATA809020
◆発行会社(リサーチ会社):GBI Research
◆発行日:2018年8月
◆ページ数:213
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single UserUSD3,995 ⇒換算¥451,435見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,990 ⇒換算¥902,870見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGBI Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GBI Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Blood Pressure Disorders Drug Development Pipeline Review, 2018
Summary

This report provides an overview of the pipeline landscape for blood pressure disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hypertension, pulmonary arterial hypertension (PAH) and hypotension, and features dormant and discontinued products.

Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in the body and the condition of the kidneys, nervous system, and blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels.

Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically do not occur until high blood pressure has reached a severe stage. There are 253 products in development for this indication.

PAH is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). There are 92 products in development for this indication.

Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms include blurred vision, dizziness, confusion, sleeplessness and weakness. Pipeline activity is much lower for hypotension than for hypertension or PAH with only seven products in development for this indication.

Molecular targets acted on by products in development for blood pressure disorders include angiotensin receptors, tyrosine protein kinases and phosphodiesterases. Companies operating in this pipeline space include Gmax Biopharm, Actelion Pharmaceuticals and Theravance Biopharma.

Scope

- Which companies are the most active within the pipeline for blood pressure disorders?
- Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

【レポートの目次】

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 8
2 Introduction 10
2.1 Blood Pressure Disorder Report Coverage 10
2.2 Hypertension – Overview 10
2.3 Hypotension – Overview 10
2.4 Pulmonary Arterial Hypertension – Overview 10
3 Therapeutics Development 11
3.1 Hypertension 11
3.2 Hypotension 32
3.3 Pulmonary Arterial Hypertension 35
4 Therapeutics Assessment 45
4.1 Hypertension 45
4.2 Hypotension 61
4.3 Pulmonary Arterial Hypertension 67
5 Companies Involved in Therapeutics Development 77
5.1 Hypertension 77
5.2 Hypotension 129
5.3 Pulmonary Arterial Hypertension 131
6 Dormant Projects 156
6.1 Hypertension 156
6.2 Hypotension 169
6.3 Pulmonary Arterial Hypertension 169
7 Discontinued Products 173
7.1 Hypertension 173
7.2 Pulmonary Arterial Hypertension 175
8 Product Development Milestones 176
8.1 Hypertension 176
8.2 Hypotension 187
8.3 Pulmonary Arterial Hypertension 197
9 Appendix 212
9.1 Methodology 212
9.2 Coverage 212
9.3 Secondary Research 212
9.4 Primary Research 212
9.5 Expert Panel Validation 212
9.6 Contact Us 213
9.7 Disclaimer 213

1.1 List of Tables
Table 1: Number of Products under Development for Hypertension 11
Table 2: Number of Products under Development by Companies Hypertension 13
Table 3: Number of Products under Development by Universities/Institutes Hypertension 18
Table 4: Products under Development by Companies Hypertension 19
Table 5: Products under Development by Universities/Institutes Hypertension 30
Table 6: Number of Products under Development for Hypotension 32
Table 7: Number of Products under Development by Companies Hypotension 33
Table 8: Products under Development by Companies Hypotension 34
Table 9: Number of Products under Development for Pulmonary Arterial Hypertension 35
Table 10: Number of Products under Development by Companies Pulmonary Arterial Hypertension 37
Table 11: Number of Products under Development by Universities/Institutes Pulmonary Arterial Hypertension 39
Table 12: Products under Development by Companies Pulmonary Arterial Hypertension 40
Table 13: Products under Development by Universities/Institutes Pulmonary Arterial Hypertension 44
Table 14: Number of Products by Stage and Target Hypertension 46
Table 15: Number of Products by Stage and Mechanism of Action Hypertension 52
Table 16: Number of Products by Stage and Route of Administration Hypertension 58
Table 17: Number of Products by Stage and Molecule Type Hypertension 60
Table 18: Number of Products by Stage and Target Hypotension 62
Table 19: Number of Products by Stage and Mechanism of Action Hypotension 63
Table 20: Number of Products by Stage and Route of Administration Hypotension 65
Table 21: Number of Products by Stage and Molecule Type Hypotension 66
Table 22: Number of Products by Stage and Target Pulmonary Arterial Hypertension 68
Table 23: Number of Products by Stage and Mechanism of Action Pulmonary Arterial Hypertension 71
Table 24: Number of Products by Stage and Route of Administration Pulmonary Arterial Hypertension 75
Table 25: Number of Products by Stage and Molecule Type Pulmonary Arterial Hypertension 76
Table 26: Hypertension - Pipeline by A1M Pharma AB 77
Table 27: Hypertension - Pipeline by Acceleron Pharma Inc 77
Table 28: Hypertension - Pipeline by Ache Laboratorios Farmaceuticos SA 78
Table 29: Hypertension - Pipeline by Actelion Pharmaceuticals Ltd 78
Table 30: Hypertension - Pipeline by Aerogen Ltd 79
Table 31: Hypertension - Pipeline by Anavex Life Sciences Corp 79
Table 32: Hypertension - Pipeline by AnGes Inc 80
Table 33: Hypertension - Pipeline by Arena Pharmaceuticals Inc 80
Table 34: Hypertension - Pipeline by Ascendia Pharmaceuticals LLC 81
Table 35: Hypertension - Pipeline by Ascendis Pharma A/S 81
Table 36: Hypertension - Pipeline by AVEO Pharmaceuticals Inc 82
Table 37: Hypertension - Pipeline by Bayer AG 82
Table 38: Hypertension - Pipeline by Bial - Portela & Ca SA 83
Table 39: Hypertension - Pipeline by Bioblue Technologies Inc 83
Table 40: Hypertension - Pipeline by Biogen Inc 83
Table 41: Hypertension - Pipeline by Biolab Farmaceutica Ltda 84
Table 42: Hypertension - Pipeline by BioRestorative Therapies Inc 84
Table 43: Hypertension - Pipeline by Boryung Pharmaceutical Co Ltd 85
Table 44: Hypertension - Pipeline by Bristol-Myers Squibb Co 85
Table 45: Hypertension - Pipeline by Camurus AB 86
Table 46: Hypertension - Pipeline by Capricor Therapeutics Inc 86
Table 47: Hypertension - Pipeline by Celsion Corp 87
Table 48: Hypertension - Pipeline by Celtaxsys Inc 87
Table 49: Hypertension - Pipeline by Chiesi Farmaceutici SpA 88
Table 50: Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp 88
Table 51: Hypertension - Pipeline by Chugai Pharmaceutical Co Ltd 89
Table 52: Hypertension - Pipeline by CJ HealthCare Corp 89
Table 53: Hypertension - Pipeline by Complexa Inc 89
Table 54: Hypertension - Pipeline by Corion Biotech Srl 90

1.2 List of Figures
Figure 1: Number of Products under Development for Hypertension 11
Figure 2: Number of Products under Development by Companies Hypertension 12
Figure 3: Number of Products under Development by Universities/Institutes Hypertension 17
Figure 4: Number of Products under Development for Hypotension 32
Figure 5: Number of Products under Development by Companies Hypotension 33
Figure 6: Number of Products under Development for Pulmonary Arterial Hypertension 35
Figure 7: Number of Products under Development by Companies Pulmonary Arterial Hypertension 36
Figure 8: Number of Products under Development by Universities/Institutes Pulmonary Arterial Hypertension 39
Figure 9: Number of Products by Top 10 Targets Hypertension 45
Figure 10: Number of Products by Stage and Top 10 Targets Hypertension 45
Figure 11: Number of Products by Top 10 Mechanism of Actions Hypertension 51
Figure 12: Number of Products by Stage and Top 10 Mechanism of Actions Hypertension 51
Figure 13: Number of Products by Top 10 Routes of Administration Hypertension 57
Figure 14: Number of Products by Stage and Top 10 Routes of Administration Hypertension 57
Figure 15: Number of Products by Top 10 Molecule Types Hypertension 59
Figure 16: Number of Products by Stage and Top 10 Molecule Types Hypertension 59
Figure 17: Number of Products by Targets Hypotension 61
Figure 18: Number of Products by Stage and Targets Hypotension 61
Figure 19: Number of Products by Mechanism of Actions Hypotension 62
Figure 20: Number of Products by Stage and Mechanism of Actions Hypotension 63
Figure 21: Number of Products by Routes of Administration Hypotension 64
Figure 22: Number of Products by Stage and Routes of Administration Hypotension 64
Figure 23: Number of Products by Molecule Types Hypotension 65
Figure 24: Number of Products by Stage and Molecule Types Hypotension 66
Figure 25: Number of Products by Top 10 Targets Pulmonary Arterial Hypertension 67
Figure 26: Number of Products by Stage and Top 10 Targets Pulmonary Arterial Hypertension 67
Figure 27: Number of Products by Top 10 Mechanism of Actions Pulmonary Arterial Hypertension 70
Figure 28: Number of Products by Stage and Top 10 Mechanism of Actions Pulmonary Arterial Hypertension 70
Figure 29: Number of Products by Routes of Administration Pulmonary Arterial Hypertension 73
Figure 30: Number of Products by Stage and Routes of Administration Pulmonary Arterial Hypertension 74
Figure 31: Number of Products by Top 10 Molecule Types Pulmonary Arterial Hypertension 75
Figure 32: Number of Products by Stage and Top 10 Molecule Types Pulmonary Arterial Hypertension 76

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 血圧異常治療薬の世界市場:開発パイプラインレビュー2018(Blood Pressure Disorders Drug Development Pipeline Review, 2018)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆